219 related articles for article (PubMed ID: 17522246)
21. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
Van Cutsem E; Siena S; Humblet Y; Canon JL; Maurel J; Bajetta E; Neyns B; Kotasek D; Santoro A; Scheithauer W; Spadafora S; Amado RG; Hogan N; Peeters M
Ann Oncol; 2008 Jan; 19(1):92-8. PubMed ID: 17785764
[TBL] [Abstract][Full Text] [Related]
22. Panitumumab: in metastatic colorectal cancer with wild-type KRAS.
Weber J; McCormack PL
BioDrugs; 2008; 22(6):403-11. PubMed ID: 18998757
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.
Sartore-Bianchi A; Moroni M; Veronese S; Carnaghi C; Bajetta E; Luppi G; Sobrero A; Barone C; Cascinu S; Colucci G; Cortesi E; Nichelatti M; Gambacorta M; Siena S
J Clin Oncol; 2007 Aug; 25(22):3238-45. PubMed ID: 17664472
[TBL] [Abstract][Full Text] [Related]
24. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
25. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
26. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.
Siano M; Molinari F; Martin V; Mach N; Früh M; Freguia S; Corradino I; Ghielmini M; Frattini M; Espeli V
Oncologist; 2017 Jul; 22(7):782-e70. PubMed ID: 28592616
[TBL] [Abstract][Full Text] [Related]
27. An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer.
Poulin-Costello M; Azoulay L; Van Cutsem E; Peeters M; Siena S; Wolf M
Target Oncol; 2013 Jun; 8(2):127-36. PubMed ID: 23625191
[TBL] [Abstract][Full Text] [Related]
28. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.
Saadeh CE; Lee HS
Ann Pharmacother; 2007 Apr; 41(4):606-13. PubMed ID: 17355997
[TBL] [Abstract][Full Text] [Related]
29. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports.
Langerak A; River G; Mitchell E; Cheema P; Shing M
Clin Colorectal Cancer; 2009 Jan; 8(1):49-54. PubMed ID: 19203897
[TBL] [Abstract][Full Text] [Related]
30. Panitumumab monotherapy as a second-line treatment in metastasised colorectal cancer: a single centre experience.
van Hellemond IE; Creemers GJ; van Warmerdam LJ; de Jong FA; Koornstra RH
Clin Oncol (R Coll Radiol); 2014 Mar; 26(3):135-41. PubMed ID: 24246276
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD
Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916
[TBL] [Abstract][Full Text] [Related]
32. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
[TBL] [Abstract][Full Text] [Related]
33. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract][Full Text] [Related]
34. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
[TBL] [Abstract][Full Text] [Related]
35. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
Berlin J; Posey J; Tchekmedyian S; Hu E; Chan D; Malik I; Yang L; Amado RG; Hecht JR
Clin Colorectal Cancer; 2007 Mar; 6(6):427-32. PubMed ID: 17531105
[TBL] [Abstract][Full Text] [Related]
36. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
37. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
38. Panitumumab (vectibix).
Gemmete JJ; Mukherji SK
AJNR Am J Neuroradiol; 2011; 32(6):1002-3. PubMed ID: 21596817
[TBL] [Abstract][Full Text] [Related]
39. Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer.
Addeo R; Caraglia M; Cerbone D; Frega N; Cimmino G; Abbruzzese A; Del Prete S
Expert Rev Anticancer Ther; 2010 Apr; 10(4):499-505. PubMed ID: 20397915
[TBL] [Abstract][Full Text] [Related]
40. Effective panitumumab treatment in patients with heavily pre-treated metastatic colorectal cancer: a case series.
Tzovaras AA; Karagiannis A; Margari C; Barla G; Ardavanis A
Anticancer Res; 2011 Mar; 31(3):1033-7. PubMed ID: 21498734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
